Ampliphi Biosciences (APHB) Stock Price, News & Analysis

Company Overview

AmpliPhi Biosciences Corporation was a biotechnology company focused on developing bacteriophage-based therapies for bacterial infections. Bacteriophages are viruses that selectively target and destroy specific bacteria, and the company’s approach was intended to address infections caused by antibiotic-resistant pathogens.

Its development pipeline included AB-SA01, an investigational phage therapy targeting Staphylococcus aureus, and AB-PA01, a therapy designed to target Pseudomonas aeruginosa. The company pursued applications in serious and difficult-to-treat infections, including respiratory and other bacterial diseases.

In 2019, AmpliPhi completed a merger with C3J Therapeutics and changed its name to Armata Pharmaceuticals, Inc. The combined company continued developing bacteriophage therapeutics, including programs originating from both organizations. AmpliPhi’s activities were primarily directed toward biotechnology research and clinical development in the United States and Australia.

Key Stats

• Today's Range: $2.75 to $3.06
• 50-Day Range: $2.78 to $5.84
• 52-Week Range: $0.15 to $1.37
• Volume: 125,555 shs
• Average Volume: 842,200 shs
• Market Capitalization: $93.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/25/2019
• Today: 10/16/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:APHB
• Previous Symbol: AMEX:APHB
• CIK: 921114
• Web: www.ampliphibio.com
• Phone: +1-804-8272524
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,469,000
• Free Float: N/A
• Market Cap: $93.04 million
• Optionable: Not Optionable
• Beta: N/A